Inogen, Inc. (INGN)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 1
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3 (shadow flag false, so no SHADOW_FST9 branch), and the name independently fails liquidity — 20-day average dollar volume ~$1.98M versus the $5M floor (recent 3-session ~$1.06M) — plus a 24.7% overnight gap on 2026-11-06 that a stop cannot cover; neither a pullback limit nor a breakout stop is actionable against a chart trading below every key MA with MACD < 0.
Company overview
Inogen, Inc. designs and distributes oxygen concentrators for patients with respiratory conditions. Its product line includes portable and stationary devices, serving patients, medical professionals, and insurers globally. The company also offers direct equipment rentals.
Fundamental
weakInogen's strong balance sheet contrasts with ongoing losses and cash burn, indicating a speculative turnaround rather than a proven business model.
Inogen pairs a genuinely strong balance sheet — no interest-bearing debt, roughly $97 million of cash and marketable securities, a current ratio near 3x and an explicit twelve-month liquidity assertion with no going-concern language — with a business that has lost money on a GAAP basis every year since 2021 and continues to burn cash, with trailing free cash flow around negative $13 million. Gross margins are compressing, U.S. revenue has declined two years running, the five-year revenue CAGR is slightly negative, and Q3 2026 brought a $10.6 million goodwill impairment as market value fell below book equity. The rental-business divestiture, an approximately $20 million cost-reduction program, a larger buyback authorization and a new CEO form a credible but unproven turnaround path. Verdict: weak, inconsistent fundamentals with elevated risk — a speculative turnaround, not a proven compounder.
Sentiment
weakRecent earnings miss and impairment have led to negative sentiment, with no immediate catalysts to offset the bearish outlook.
Inogen's dominant near-term driver is the 2026-11-05 Q3 print — revenue -2.4% to $77.2M, international sales -9%, a $0.42 EPS miss and a revenue shortfall, a $10.6M impairment widening the GAAP loss and a $65–68M Q4 guide implying a sequential step-down — read bearish across all three negatively scored in-window items, with the only other in-window events (a CEO transition with a named successor, the completed Rotech rental divestiture, a Buy-maintained target cut to $9.5) neutral at best. The measured sentiment delta is indeterminate because the baseline held only two scored items, though item-level evidence is a determinate constructive-to-negative turn, and with a moderate red-flag cap applied for sharply deteriorating ≤14-day sentiment with no offsetting bullish catalyst the setup resolves at the weak end of that capped range.
Technical
very weakInogen's stock is trading below all key averages, with deteriorating momentum and no signs of a bullish reversal.
Broken post-earnings structure. Price 5.69 sits below every key average — SMA20 6.64, SMA50 6.00, SMA200 6.23, EMA9 6.11, EMA21 6.32 — and below the 9/21 WMA and DEMA/TEMA stack (5.98/6.45/6.02/5.67). MACD line -0.10 has crossed under its signal 0.10 with the histogram widening to -0.20, i.e. momentum is deteriorating, not repairing. ADX14 39.37 is elevated and rising; read direction-agnostically against a price under all MAs, that is a strong DOWN trend, not a bullish compression. RSI14 36.64 and Williams %R -73.22 are weak without reaching a capitulation extreme, and the 11-06 reflex bounce off 5.05 has already failed back to 5.69 on fading volume. Chart quality is therefore bearish/broken (score 1). Tradability is separately blocked by fundamentalScore 2 and qualitativeScore 2 (both below the required floor of 3), by a 20-day average dollar volume of ~$1.98M against the $5M floor, and by a 24.7% overnight gap (11-05 close 6.75 → 11-06 open 5.08) that a protective stop cannot cover.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

